Xcout Intel
Organon & Co. competitors & alternatives
The 12 closest competitors and alternatives to Organon & Co. among pharmaceuticals companies — ranked by similarity to what Organon & Co. actually does, not by market-cap band.
Subscribe to see Organon & Co.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Organon & Co.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Organon & Co. at a glance
Organon & Co. is a pharmaceuticals company headquartered in Jersey City, United States. It is publicly listed (OGN) with a market capitalisation of $3.6B. Xcout tracks 26 named people at Organon & Co., including Joseph T. Morrissey Jr. (Chief Executive Officer).
Organon & Co. leadership
- Joseph T. Morrissey Jr.Chief Executive Officer
- Joseph MorrisseyChief Executive Officer
- Matthew WalshExecutive Vice President & Chief Financial Officer
- Juan Camilo Arjona FerreiraExecutive Vice President, Head of Research & Development and Chief Medical Officer
- Rachel A. StahlerExecutive VP, Chief Information Officer and Chief Digital & Growth Officer
- Aaron FalcioneExecutive Vice President & Chief Human Resources Officer
20 more named people on record for Organon & Co., with roles, board committees and tenure — see the full roster →
Top 12 Organon & Co. competitors
Ranked by semantic similarity — how close each company is to Organon & Co. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Ferring Pharmaceuticals is a specialty biopharmaceutical company that develops and delivers treatments in reproductive medicine, maternal health, gastroenterology, urology, and uro-oncology. The company focuses on helping people build families, supporting maternal and infant health, and providing therapeutic solutions for various medical conditions worldwide.
Similar pharmaceuticals company
Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.
Similar pharmaceuticals company
Jagsonpal Pharmaceuticals Limited is a Delhi-based public pharmaceutical company founded in 1978. Headquartered in Gurugram, Haryana, the company specializes in women's health and pharmaceutical products.
Similar pharmaceuticals company
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.
Similar pharmaceuticals company
Theramex is a British pharmaceutical company based in London which produces women's health products focusing on contraception, fertility, menopause and osteoporosis.
Biotech
ObsEva is a biopharmaceutical company headquartered in Geneva, Switzerland, specifically in Plan-les-Ouates. The company focuses on developing and commercializing novel therapies for women's reproductive health. ObsEva has entered into global license agreements, such as with Organon, for the development of certain compounds.
Biotechnology
Asieris Pharmaceuticals is a global innovative biopharmaceutical company founded in March 2010 that specializes in the development of treatments for genitourinary tumors and women's health.
Similar pharmaceuticals company
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
Similar pharmaceuticals company
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Similar pharmaceuticals company
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Similar pharmaceuticals company
Bristol-Myers Squibb Company is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, and commercialization of pharmaceutical products. Its extensive portfolio of medicines targets a wide array of serious medical conditions, including those in the fields of hematology, oncology, cardiovascular health, immunology, fibrotic disorders, neuroscience, and COVID-19. The company's prominent therapies include Revlimid, an oral immunomodulator prescribed for multiple myeloma; Eliquis, an oral inhibitor used to lower the risk of stroke/systemic embolism in non-valvular atrial fibrillation and to treat deep vein thrombosis/pulmonary embolism; and Opdivo, a key anti-cancer agent. Additional significant products are Pomalyst/Imnovid for multiple myeloma; Orencia, which addresses active rheumatoid arthritis and psoriatic arthritis; and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. Its lineup further features Yervoy for unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy; Reblozyl for adult patients experiencing anemia due to beta thalassemia; and Empliciti, also for multiple myeloma. Recent innovations include Zeposia for relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for specific types of B-cell lymphoma; Inrebic, an oral kinase inhibitor for myelofibrosis; and Onureg for adult patients with acute myeloid leukemia. Bristol-Myers Squibb distributes its pharmaceutical offerings to a broad network of customers, encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and various government agencies. The organization, established in 1887 and previously known as Bristol-Myers Company, is headquartered in New York, New York.
Similar pharmaceuticals company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Organon & Co. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Organon & Co.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →